RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 144 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $594 | – | 77,011 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CRV, LLC | 733,986 | $16,889,000 | 37.30% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 1,388,889 | $31,958,000 | 5.87% |
| Yong Rong (HK) Asset Management Ltd | 377,000 | $8,675,000 | 5.69% |
| Samsara BioCapital, LLC | 752,939 | $17,325,000 | 2.72% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $34,728,000 | 2.04% |
| Spouting Rock Asset Management, LLC | 52,851 | $1,216,000 | 0.61% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 661,703 | $15,226,000 | 0.43% |
| Laurion Capital Management LP | 3,923,713 | $90,285,000 | 0.38% |
| Casdin Capital, LLC | 548,156 | $12,613,000 | 0.31% |
| Baillie Gifford | 22,061,374 | $507,632,000 | 0.27% |